UCB S.A. Stock
We can see a decrease in the price for UCB S.A.. Compared to yesterday it has lost -€4.000 (-1.490%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for UCB S.A. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of UCB S.A. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of UCB S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| UCB S.A. | -1.490% | 4.900% | 13.824% | 42.758% | 12.721% | 257.658% | 204.784% |
| Bayer AG ADR | -3.390% | 1.852% | 13.402% | 115.686% | 25.000% | -21.429% | -21.986% |
| GSK plc ADR | -0.990% | 20.238% | 19.104% | 38.736% | 20.813% | 55.864% | 37.415% |
| Novartis AG ADR | -1.150% | 5.221% | 11.017% | 23.585% | 10.549% | 64.573% | 73.510% |
Comments
UCB (OTCMKTS:UCBJF) had its "overweight" rating reaffirmed by analysts at Stephens.
Show more
Ratings data for UCBJF provided by MarketBeat
UCB (OTCMKTS:UCBJF) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Show more
Ratings data for UCBJF provided by MarketBeat
UCB (OTCMKTS:UCBJF) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Show more
Ratings data for UCBJF provided by MarketBeat